Compare Schlumberger NV (SLB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Zoetis Inc — how do they compare? Schlumberger NV trades at $52.83 (market cap $79.67B), while Zoetis Inc trades at $73 (market cap $31.14B). The key difference: Schlumberger NV is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| SLB | ZTS | |
|---|---|---|
Market Cap | $79.67B | $31.14B |
Sector | Energy | Health |
52-Week High | $58.01 | $156.76 |
52-Week Low | $31.72 | $71.91 |
Enterprise Value | $88.40B | $38.70B |
Dividend Yield | 2.2% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $52.96, down 0.45% on the day, with a bullish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.55, and maintains a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53%, though margins have softened from prior years. Recent news highlights growth in digital and offshore segments, offset by Middle East challenges.
The outlook for SLB is positive, driven by earnings beats and robust analyst support, but risks include regional volatility and margin pressure. Upside potential exists if digital and production gains accelerate, yet investors must weigh debt levels and geopolitical headwinds against the stock's current valuation near 52-week highs.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
